Discover investment opportunities in Small CAPSTOCKS2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small CAPSTOCKS2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small CAPSTOCKS2024 using our Smart AI Filter.
9 stocks found for "Small CAPSTOCKS2024"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.01 | ±61.6% | -6.4 | 0.00% | |||
0.65 | ±42.2% | -9.5 | 0.00% | |||
1.40 | ±84.7% | 15.6 | 0.00% | |||
0.38 | ±52.9% | -81.6 | 0.00% | |||
1.16 | ±33.0% | 25.7 | 0.00% | |||
0.63 | ±44.5% | 8.1 | 1.47% | |||
0.84 | ±63.9% | -43.5 | 0.84% | |||
0.77 | ±39.0% | 16.9 | 0.00% | |||
0.90 | ±81.9% | 0.0 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does the historical performance of RMBS and THRM compare in periods of economic growth?
A: Historically, RMBS (Rambus Inc.) has shown consistent growth due to its focus on technology and semiconductor investments, whereas THRM (Gentherm Inc.) benefits from advancements in climate-controlled seating and other automotive technologies. Both have thrived in growth phases driven by technological adoption and consumer spending increases.
Q: What factors contribute to FLGT's potential for income generation?
A: FLGT (Fulgent Genetics Inc.) typically reinvests its earnings for growth, focusing on genomic testing advancements. While not a traditional dividend stock, its growth potential could attract investors looking for capital appreciation in the genetic testing sector.
Q: What are the risks associated with investing in ACLS, particularly in a volatile market?
A: Investors in ACLS (Axcelis Technologies Inc.) should consider its exposure to semiconductor market fluctuations, as demand for chip manufacturing equipment varies with tech cycles. Economic downturns can impact industry capital expenditure budgets, posing revenue risks.
Q: Why might BCPC be considered a stable investment in the current economic climate?
A: BCPC (Balchem Corporation) operates across multiple stable sectors, including nutrition, health, and specialty products. Its diversified portfolio may appeal to investors seeking stability and resilience against market volatility.
Q: How does INBX position itself within the biotechnology sector for long-term growth?
A: INBX (Inhibrx Inc.) leverages its robust pipeline of clinical candidates targeting oncology and rare diseases, aiming for both innovation and collaboration. Its focus on licensed technology and proprietary research may suggest long-term growth potential in biotech.
Q: In what ways do SLP and PRLB offer technological advantages within their industries?
A: SLP (Simulations Plus Inc.) provides advanced software for pharmaceutical research, enhancing drug discovery efficiency. PRLB (Proto Labs Inc.) revolutionizes manufacturing with quick-turn custom prototyping and injection molding services, highlighting their tech-driven edge.
The consensus price target hints at a 25.6% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read morePROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.5 per share a year ago.
Read more